EXEL
Exelixis, Inc.$44.88+0.23 (+0.52%)Prev Close$44.65·MCap$11.92B·P/E15.33·Vol1.35M·Yield—
▲
Buys (12M)
1
$1.19M
▼
Sells (12M)
26
$78.56M
◆
Net Activity
Net Seller
$77.37M
●
Active Insiders
16
last 12 mo
Over the past 12 months, insider activity at Exelixis, Inc. (EXEL) has been dominated by selling, with 1 insider purchase totaling $1.19M and 26 insider sales totaling $78.56M. The most recent insider transaction was by Aftab Dana (officer: EVP, Research and Development), who sold $2.13M worth of shares on Feb 26, 2026. Exelixis, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $11.92B.
EXEL Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | Aftab Dana | officer: EVP, Research and Development | Sell | 47,918 | $44.50 | $2.13M | 616,106 |
| Feb 19, 2026 | Aftab Dana | EVP, Research and Development | Sell | 29,873 | $44.35 | $1.32M | 0 |
| Feb 18, 2026 | MORRISSEY MICHAEL | President and CEO | Sell | 489,996 | $43.92 | $21.52M | 0 |
| Feb 18, 2026 | WYSZOMIERSKI JACK L | Director | Sell | 99,574 | $44.01 | $4.38M | 0 |
| Feb 17, 2026 | Smith Julie | Director | Sell | 106,539 | $44.00 | $4.69M | 0 |
| Feb 15, 2026 | Aftab Dana | EVP, Research and Development | Sell | 39,205 | $43.92 | $1.72M | 0 |
| Feb 15, 2026 | Haley Patrick J. | EVP, Commercial | Sell | 99,297 | $43.64 | $4.33M | 0 |
| Feb 15, 2026 | Hefti Brenda | SVP and General Counsel | Sell | 24,099 | $43.99 | $1.06M | 0 |
| Feb 13, 2026 | Eckhardt Sue Gail | Director | Sell | 3,856 | $43.79 | $168.9K | 0 |
| Feb 13, 2026 | Oliver Bob | Director | Sell | 30,250 | $43.81 | $1.33M | 0 |
| Feb 13, 2026 | Senner Christopher J. | EVP and CFO | Sell | 100,765 | $43.53 | $4.39M | 0 |
| Nov 26, 2025 | JOHNSON DAVID EDWARD | Director | Buy | 27,532 | $43.12 | $1.19M | 1,553,262 |
| Nov 24, 2025 | Haley Patrick J. | EVP, Commercial | Sell | 72,230 | $42.18 | $3.05M | 402,072 |
| Nov 13, 2025 | PAPADOPOULOS STELIOS | Director | Sell | 100,000 | $43.55 | $4.36M | 1,189,228 |
| Nov 13, 2025 | Beckerle Mary C | Director | Sell | 24,622 | $41.93 | $1.03M | 40,218-38% |
| Nov 13, 2025 | Aftab Dana | EVP, Research and Development | Sell | 48,383 | $42.50 | $2.06M | 664,778 |
| Jun 4, 2025 | Eckhardt Sue Gail | Director | Sell | 18,838 | $42.74 | $805.1K | 21,384-47% |
| Jun 4, 2025 | WYSZOMIERSKI JACK L | Director | Sell | 7,535 | $43.09 | $324.7K | 358,882 |
| May 22, 2025 | Haley Patrick J. | EVP, Commercial | Sell | 34,387 | $44.06 | $1.52M | 412,072 |
| May 22, 2025 | Heyman Tomas J. | Director | Sell | 4,544 | $44.29 | $201.3K | 32,470 |
| May 16, 2025 | PAPADOPOULOS STELIOS | Director | Sell | 36,508 | $44.35 | $1.62M | 1,279,416 |
| May 16, 2025 | Haley Patrick J. | EVP, Commercial | Sell | 136,383 | $47.58 | $6.49M | 491,164 |
| May 16, 2025 | Hessekiel Jeffrey | EVP & General Counsel | Sell | 25,000 | $46.18 | $1.15M | 693,396 |
| May 16, 2025 | Peterson Amy C. | EVP Prod Dev & Med Aff & CMO | Sell | 72,776 | $45.47 | $3.31M | 465,393 |
| May 16, 2025 | POSTE GEORGE | Director | Sell | 20,634 | $45.99 | $949.0K | 169,020 |
| May 16, 2025 | Senner Christopher J. | EVP and CFO | Sell | 100,000 | $46.00 | $4.60M | 967,842 |
| May 5, 2025 | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 1,508 | $39.00 | $58.8K | 693,181 |
| Mar 5, 2025 | Haley Patrick J. | EVP, Commercial | Sell | 10,000 | $38.80 | $388.0K | 341,028 |
| Feb 28, 2025 | WYSZOMIERSKI JACK L | Director | Sell | 8,768 | $37.80 | $331.4K | 356,605 |
| Feb 28, 2025 | Smith Julie | Director | Sell | 73,808 | $38.00 | $2.80M | 10,778-87% |
| Feb 26, 2025 | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 26,987 | $36.75 | $991.8K | 511,908 |
| Feb 26, 2025 | Haley Patrick J. | EVP, Commercial | Sell | 52,636 | $36.98 | $1.95M | 303,310 |
| Feb 26, 2025 | Oliver Bob | Director | Sell | 18,647 | $37.25 | $694.6K | 33,514-36% |
| Feb 26, 2025 | Senner Christopher J. | EVP and CFO | Sell | 29,314 | $36.14 | $1.06M | 779,607 |
| Feb 19, 2025 | Freire Maria C | Director | Sell | 44,114 | $34.94 | $1.54M | 91,007-33% |
| Feb 19, 2025 | POSTE GEORGE | Director | Sell | 15,874 | $34.74 | $551.5K | 169,020 |
| Feb 19, 2025 | Beckerle Mary C | Director | Sell | 12,210 | $34.88 | $425.9K | 34,262-26% |
| Feb 19, 2025 | Eckhardt Sue Gail | Director | Sell | 11,568 | $35.02 | $405.1K | 34,262-25% |
| Dec 2, 2024 | Hessekiel Jeffrey | EVP & General Counsel | Sell | 60,000 | $36.67 | $2.20M | 486,059 |
| Nov 26, 2024 | Haley Patrick J. | EVP, Commercial | Sell | 10,000 | $35.27 | $352.7K | 278,665 |
| Nov 19, 2024 | Haley Patrick J. | EVP, Commercial | Sell | 41,588 | $34.36 | $1.43M | 308,046 |
| Nov 7, 2024 | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 96,986 | $35.00 | $3.39M | 498,945 |
| Nov 5, 2024 | Hessekiel Jeffrey | EVP & General Counsel | Sell | 50,000 | $34.13 | $1.71M | 530,325 |
| Nov 5, 2024 | POSTE GEORGE | Director | Sell | 30,000 | $34.00 | $1.02M | 169,020 |
| Nov 1, 2024 | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 1,162 | $31.40 | $36.5K | 498,945 |
| Oct 30, 2024 | Hessekiel Jeffrey | EVP & General Counsel | Sell | 25,000 | $28.39 | $709.8K | 580,325 |
| Sep 25, 2024 | Hessekiel Jeffrey | EVP & General Counsel | Sell | 25,000 | $26.38 | $659.5K | 605,325 |
| Aug 28, 2024 | Hessekiel Jeffrey | EVP, General Counsel & Sec | Sell | 20,000 | $25.79 | $515.8K | 630,325 |
| Aug 16, 2024 | Freire Maria C | Director | Sell | 8,250 | $26.56 | $219.1K | 91,007 |
| Aug 14, 2024 | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 20,883 | $27.06 | $565.1K | 500,107 |
Showing 1–50 of 121
1 / 3
EXEL Insider Buying Activity
The following table shows recent insider purchases of Exelixis, Inc. (EXEL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Nov 26, 2025 | JOHNSON DAVID EDWARD | Director | Buy | 27,532 | $43.12 | $1.19M | 1,553,262 |
EXEL Insider Selling Activity
The following table shows recent insider sales of Exelixis, Inc. (EXEL) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | Aftab Dana | officer: EVP, Research and Development | Sell | 47,918 | $44.50 | $2.13M | 616,106 |
| Feb 19, 2026 | Aftab Dana | EVP, Research and Development | Sell | 29,873 | $44.35 | $1.32M | 0 |
| Feb 18, 2026 | MORRISSEY MICHAEL | President and CEO | Sell | 489,996 | $43.92 | $21.52M | 0 |
| Feb 18, 2026 | WYSZOMIERSKI JACK L | Director | Sell | 99,574 | $44.01 | $4.38M | 0 |
| Feb 17, 2026 | Smith Julie | Director | Sell | 106,539 | $44.00 | $4.69M | 0 |
| Feb 15, 2026 | Aftab Dana | EVP, Research and Development | Sell | 39,205 | $43.92 | $1.72M | 0 |
| Feb 15, 2026 | Haley Patrick J. | EVP, Commercial | Sell | 99,297 | $43.64 | $4.33M | 0 |
| Feb 15, 2026 | Hefti Brenda | SVP and General Counsel | Sell | 24,099 | $43.99 | $1.06M | 0 |
| Feb 13, 2026 | Eckhardt Sue Gail | Director | Sell | 3,856 | $43.79 | $168.9K | 0 |
| Feb 13, 2026 | Oliver Bob | Director | Sell | 30,250 | $43.81 | $1.33M | 0 |
| Feb 13, 2026 | Senner Christopher J. | EVP and CFO | Sell | 100,765 | $43.53 | $4.39M | 0 |
| Nov 24, 2025 | Haley Patrick J. | EVP, Commercial | Sell | 72,230 | $42.18 | $3.05M | 402,072 |
| Nov 13, 2025 | PAPADOPOULOS STELIOS | Director | Sell | 100,000 | $43.55 | $4.36M | 1,189,228 |
| Nov 13, 2025 | Beckerle Mary C | Director | Sell | 24,622 | $41.93 | $1.03M | 40,218-38% |
| Nov 13, 2025 | Aftab Dana | EVP, Research and Development | Sell | 48,383 | $42.50 | $2.06M | 664,778 |
| Jun 4, 2025 | Eckhardt Sue Gail | Director | Sell | 18,838 | $42.74 | $805.1K | 21,384-47% |
| Jun 4, 2025 | WYSZOMIERSKI JACK L | Director | Sell | 7,535 | $43.09 | $324.7K | 358,882 |
| May 22, 2025 | Haley Patrick J. | EVP, Commercial | Sell | 34,387 | $44.06 | $1.52M | 412,072 |
| May 22, 2025 | Heyman Tomas J. | Director | Sell | 4,544 | $44.29 | $201.3K | 32,470 |
| May 16, 2025 | PAPADOPOULOS STELIOS | Director | Sell | 36,508 | $44.35 | $1.62M | 1,279,416 |
| May 16, 2025 | Haley Patrick J. | EVP, Commercial | Sell | 136,383 | $47.58 | $6.49M | 491,164 |
| May 16, 2025 | Hessekiel Jeffrey | EVP & General Counsel | Sell | 25,000 | $46.18 | $1.15M | 693,396 |
| May 16, 2025 | Peterson Amy C. | EVP Prod Dev & Med Aff & CMO | Sell | 72,776 | $45.47 | $3.31M | 465,393 |
| May 16, 2025 | POSTE GEORGE | Director | Sell | 20,634 | $45.99 | $949.0K | 169,020 |
| May 16, 2025 | Senner Christopher J. | EVP and CFO | Sell | 100,000 | $46.00 | $4.60M | 967,842 |
| May 5, 2025 | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 1,508 | $39.00 | $58.8K | 693,181 |
| Mar 5, 2025 | Haley Patrick J. | EVP, Commercial | Sell | 10,000 | $38.80 | $388.0K | 341,028 |
| Feb 28, 2025 | WYSZOMIERSKI JACK L | Director | Sell | 8,768 | $37.80 | $331.4K | 356,605 |
| Feb 28, 2025 | Smith Julie | Director | Sell | 73,808 | $38.00 | $2.80M | 10,778-87% |
| Feb 26, 2025 | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 26,987 | $36.75 | $991.8K | 511,908 |
| Feb 26, 2025 | Haley Patrick J. | EVP, Commercial | Sell | 52,636 | $36.98 | $1.95M | 303,310 |
| Feb 26, 2025 | Oliver Bob | Director | Sell | 18,647 | $37.25 | $694.6K | 33,514-36% |
| Feb 26, 2025 | Senner Christopher J. | EVP and CFO | Sell | 29,314 | $36.14 | $1.06M | 779,607 |
| Feb 19, 2025 | Freire Maria C | Director | Sell | 44,114 | $34.94 | $1.54M | 91,007-33% |
| Feb 19, 2025 | POSTE GEORGE | Director | Sell | 15,874 | $34.74 | $551.5K | 169,020 |
| Feb 19, 2025 | Beckerle Mary C | Director | Sell | 12,210 | $34.88 | $425.9K | 34,262-26% |
| Feb 19, 2025 | Eckhardt Sue Gail | Director | Sell | 11,568 | $35.02 | $405.1K | 34,262-25% |
| Dec 2, 2024 | Hessekiel Jeffrey | EVP & General Counsel | Sell | 60,000 | $36.67 | $2.20M | 486,059 |
| Nov 26, 2024 | Haley Patrick J. | EVP, Commercial | Sell | 10,000 | $35.27 | $352.7K | 278,665 |
| Nov 19, 2024 | Haley Patrick J. | EVP, Commercial | Sell | 41,588 | $34.36 | $1.43M | 308,046 |
| Nov 7, 2024 | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 96,986 | $35.00 | $3.39M | 498,945 |
| Nov 5, 2024 | Hessekiel Jeffrey | EVP & General Counsel | Sell | 50,000 | $34.13 | $1.71M | 530,325 |
| Nov 5, 2024 | POSTE GEORGE | Director | Sell | 30,000 | $34.00 | $1.02M | 169,020 |
| Nov 1, 2024 | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 1,162 | $31.40 | $36.5K | 498,945 |
| Oct 30, 2024 | Hessekiel Jeffrey | EVP & General Counsel | Sell | 25,000 | $28.39 | $709.8K | 580,325 |
| Sep 25, 2024 | Hessekiel Jeffrey | EVP & General Counsel | Sell | 25,000 | $26.38 | $659.5K | 605,325 |
| Aug 28, 2024 | Hessekiel Jeffrey | EVP, General Counsel & Sec | Sell | 20,000 | $25.79 | $515.8K | 630,325 |
| Aug 16, 2024 | Freire Maria C | Director | Sell | 8,250 | $26.56 | $219.1K | 91,007 |
| Aug 14, 2024 | Aftab Dana | CSO/EVP Disc & Trans Research | Sell | 20,883 | $27.06 | $565.1K | 500,107 |
EXEL Insiders
Similar Stocks to EXEL
VRTX
Vertex Pharmaceuticals Incorporated
$429.47+0.81%
$111.71B
REGN
Regeneron Pharmaceuticals, Inc.
$734.06-1.39%
$77.87B
ALNY
Alnylam Pharmaceuticals, Inc.
$303.44-1.64%
$41.24B
INSM
Insmed Incorporated
$135.11-0.64%
$30.79B
RVMD
Revolution Medicines, Inc.
$144.62+9.92%
$29.51B
UTHR
United Therapeutics Corporation
$566.69+0.03%
$25.13B
MRNA
Moderna, Inc.
$47.16-3.17%
$21.42B
RPRX
Royalty Pharma plc
$49.40-0.50%
$21.20B